Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3293)	7/30/2015 9:41:37 AM
From: Jibacoa	Respond to of 3722

SGYP was up 18.8% at the opening. It opened with an UG and is still up 13,64% with volume now > 4.38Ms. <g> It announced some data about its PIII for idiopathic chronic constipation.<g> finance.yahoo.com Bernard

To: Jibacoa who wrote (3293)	7/30/2015 10:36:21 AM
From: Jibacoa	Respond to of 3722

ASND also opened with a good UG.<g> It was up 19.46 % at the opening, but only 1.40% at present, with volume now close to 169Ks.<g> ASND is a Denmark Co, and announced some results of its PII of its weekly growth hormone, based on its TransCon technology.<g> The full results are expected in October. finance.yahoo.com That product will compete with PFE's product which is currently also been tested. PFE's long acting GH is based on the TPC technology that OPKO bought from Prolor and licensed to PFE.<g> But ASND also has other long acting hormones been tested, based on its TransCon technology, including TransCon Treprostinil for PAH, and TransCon Ranibizumab for AMD on which it is collaborating with Genentech, and will compete not only with Lucentis, but also with the product from OPHT.<g> It also has some TransCon peptides in collaboration with Sanofi, which are intended to ptoduce some long acting insulin.<g> Bernard